- Home
- SGLY vs BMRA Comparison
SGLY vs BMRA Comparison
Compare SGLY & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | BMRA |
|---|---|---|
| Founded | 2001 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 6.3M |
| IPO Year | 2008 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SGLY | BMRA |
|---|---|---|
| Price | $0.40 | $2.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.6K | 9.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,813,193.00 | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.40 |
| 52 Week High | $1.86 | $4.60 |
Technical Indicators
Market Signals| Indicator | SGLY | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 44.56 |
| Support Level | $0.34 | N/A |
| Resistance Level | $0.43 | $2.40 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.24 | 52.79 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.